Sarepta Therapeutics (NASDAQ:SRPT) creates RNA-based drugs for the treatment of serious and life threatening diseases. Its most advanced candidate is an intravenously delivered treatment for Duchenne Muscular Dystrophy [DMD]. In addition to the promising DMD program, the company also has drugs for the treatment of ebola, Marburg and influenza viruses in clinical Phase 1 trials.
RNA drugs without the R
The company uses a phosphorodiamidate morpholino oligomer [PMO] antisense platform that allows for a diverse range of therapeutic candidates. The technology is far simpler than its name implies. Natural RNA is a string of nucleic acid bases (adenine, cytosine, guanine, and thymine) held together by backbone of recurring ribose rings. Sarepta's PMOs use the same nucleic acid bases,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|